The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat

Blood Coagul Fibrinolysis. 2001 Jul;12(5):349-57. doi: 10.1097/00001721-200107000-00003.

Abstract

Danaparoid and heparin, on the basis of anti-activated factor X (anti-FXa) activity, were equipotent in accelerating the rate of interaction of FXa and antithrombin III. In rat tissue factor-induced disseminated intravascular coagulation (DIC) models, an intravenous administration of danaparoid inhibited the decrease in plasma fibrinogen and platelet counts and the increase in serum fibrinogen degradation products. Expressed on the basis of anti-FXa activity, these effects were comparable with those of dalteparin and heparin. In rat mesenteric small artery and vein, less bleeding was observed after intravenous administration of danaparoid than after dalteparin or heparin. Danaparoid did not affect adenosine diphosphate- or collagen-induced platelet aggregation, and showed weaker inhibitory effects on aggregation induced by thrombin, or collagen + thrombin, than did dalteparin or heparin. These findings suggest that danaparoid may be useful for the prevention of DIC and has less tendency to cause bleeding than dalteparin or heparin, probably as a result of its weaker ability to inhibit platelet aggregation.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Anticoagulants / administration & dosage
  • Anticoagulants / pharmacology*
  • Antithrombin III / pharmacology
  • Bleeding Time
  • Chondroitin Sulfates / administration & dosage
  • Chondroitin Sulfates / pharmacology
  • Dalteparin / administration & dosage
  • Dalteparin / pharmacology
  • Dermatan Sulfate / administration & dosage
  • Dermatan Sulfate / pharmacology
  • Disease Models, Animal
  • Disseminated Intravascular Coagulation / chemically induced
  • Disseminated Intravascular Coagulation / complications
  • Disseminated Intravascular Coagulation / drug therapy*
  • Drug Combinations
  • Drug Evaluation, Preclinical
  • Enzyme Inhibitors / pharmacology
  • Factor Xa / metabolism
  • Factor Xa Inhibitors
  • Heparin / administration & dosage
  • Heparin / pharmacology
  • Heparitin Sulfate / administration & dosage
  • Heparitin Sulfate / pharmacology
  • Kinetics
  • Male
  • Platelet Aggregation / drug effects
  • Rats
  • Rats, Wistar
  • Risk Assessment
  • Thromboplastin / pharmacology*

Substances

  • Anticoagulants
  • Drug Combinations
  • Enzyme Inhibitors
  • Factor Xa Inhibitors
  • Dermatan Sulfate
  • Antithrombin III
  • Heparin
  • Chondroitin Sulfates
  • Thromboplastin
  • Heparitin Sulfate
  • danaparoid
  • Factor Xa
  • Dalteparin